SAVANNAH, Georgia — There’s no medical treatment for Charcot-Marie-Tooth (CMT) disease, a debilitating neurologic disorder that’s both progressive and incurable. But now, nerve specialists ...
and an estimated one million individuals with an inherited degenerative nerve condition called Charcot–Marie–Tooth disease type 2 (CMT2). Peripheral neuropathy can cause severe disability and ...
The SynGAP Research Fund 501(c)(3) has awarded a pair of grants to Dr. Clement Chow, a geneticist and Associate Professor in the Department of Human Genetics at the University of Utah. These grants ...
Mitochondria In Motion Inc. has identified new N-(trans-4-hydroxycyclohexyl)-6-phenylhexanamide derivatives acting as mitofusin activators and reported to be useful for the treatment of Alzheimer’s, ...
Charcot-Marie-Tooth affects 1 in 2,500 people or approximately 2.6 million people worldwide. The disease causes progressive nerve damage and those with CMT ... Currently there is no cure and treatment ...
Other laboratory tests to confirm the condition. Treatments can help manage condition, no known cure Diagnosed by medical professional Requires lab test or imaging A lifelong condition Certain ...
Treatment with CKD-510 restored the shortened ... including the application to neurodegenerative diseases such as Charcot-Marie-Tooth disease (CMT) 1, 2. The axonal transport of intracellular ...
French biotech Pharnext has seen the value of its shares collapse after it revealed that its lead drug, a treatment for Charcot-Marie-Tooth (CMT) disease, failed to make the grade in a phase 3 trial.